The molecular basis of resistance to isoniazid, rifampin, and pyrazinamide in Mycobacterium tuberculosis

被引：0
|
作者：
Akos Somoskovi
Linda M Parsons
Max Salfinger
机构：
[1] Wadsworth Center,New York State Department of Health
[2] Semmelweis University,Department of Respiratory Medicine
[3] Albany Medical College,Department of Medicine
[4] School of Public Health,Department of Biomedical Sciences
[5] University at Albany,undefined
来源：
Respiratory Research | / 2卷
关键词：
drug resistance; isoniazid; pyrazinamide; rifampin;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
Multidrug-resistant (MDR) strains of Mycobacterium tuberculosis have emerged worldwide. In many countries and regions, these resistant strains constitute a serious threat to the efficacy of tuberculosis control programs. An important element in gaining control of this epidemic is developing an understanding of the molecular basis of resistance to the most important antituberculosis drugs: isoniazid, rifampin, and pyrazinamide. On the basis of this information, more exacting laboratory testing, and ultimately more appropriate and timely treatment regimens, can be developed.
引用
收藏
相关论文
共 50 条
  • [1] The molecular basis of resistance to isoniazid, rifampin, and pyrazinamide in Mycobacterium tuberculosis
    Somoskovi, A
    Parsons, LM
    Salfinger, M
    [J]. RESPIRATORY RESEARCH, 2001, 2 (03) : 164 - 168
  • [2] The molecular basis of isoniazid resistance in Mycobacterium tuberculosis
    Heym, B
    [J]. MULTI-DRUG RESISTANCE IN EMERGING AND RE-EMERGING DISEASES, 2000, : 97 - 108
  • [3] Molecular identification of mutations conferring resistance to rifampin, isoniazid and pyrazinamide among Mycobacterium tuberculosis isolates from Iran
    Haratiasl, Ahad Ali
    Hamzelou, Gholamreza
    Amini, Sirus
    Kardan-Yamchi, Jalil
    Haeili, Mehri
    Heidari, Fereshteh
    Feizabadi, Mohammad Mehdi
    [J]. JOURNAL OF CHEMOTHERAPY, 2020, 32 (02) : 75 - 82
  • [4] TREATMENT OF TUBERCULOSIS WITH ISONIAZID, RIFAMPIN AND PYRAZINAMIDE
    BRANDLI, O
    DREHER, D
    MORGER, D
    [J]. SCHWEIZERISCHE MEDIZINISCHE WOCHENSCHRIFT, 1993, 123 (25) : 1300 - 1306
  • [5] Detection of resistance to isoniazid, rifampin, and streptomycin in clinical isolates of Mycobacterium tuberculosis by molecular methods
    Nachamkin, I
    Kang, C
    Weinstein, MP
    [J]. CLINICAL INFECTIOUS DISEASES, 1997, 24 (05) : 894 - 900
  • [6] Molecular analysis of isoniazid and rifampin resistance in Mycobacterium tuberculosis isolates recovered from Barcelona
    Coll, P
    Aragón, LM
    Alcaide, F
    Espasa, M
    Garrigó, M
    González, J
    Manterola, JM
    Orús, P
    Salvadó, M
    [J]. MICROBIAL DRUG RESISTANCE, 2005, 11 (02) : 107 - 114
  • [7] The molecular basis of pyrazinamide activity on Mycobacterium tuberculosis PanD
    Sun, Qingan
    Li, Xiaojun
    Perez, Lisa M.
    Shi, Wanliang
    Zhang, Ying
    Sacchettini, James C.
    [J]. NATURE COMMUNICATIONS, 2020, 11 (01)
  • [8] The molecular basis of pyrazinamide activity on Mycobacterium tuberculosis PanD
    Qingan Sun
    Xiaojun Li
    Lisa M. Perez
    Wanliang Shi
    Ying Zhang
    James C. Sacchettini
    [J]. Nature Communications, 11
  • [9] Pyrosequencing for Rapid Molecular Detection of Rifampin and Isoniazid Resistance in Mycobacterium tuberculosis Strains and Clinical Specimens
    Garcia-Sierra, N.
    Lacoma, A.
    Prat, C.
    Haba, L.
    Maldonado, J.
    Ruiz-Manzano, J.
    Gavin, P.
    Samper, S.
    Ausina, V.
    Dominguez, J.
    [J]. JOURNAL OF CLINICAL MICROBIOLOGY, 2011, 49 (10) : 3683 - 3686
  • [10] Molecular characterization of isoniazid and rifampin resistance of Mycobacterium tuberculosis clinical isolates from Malatya, Turkey
    Aktas, E
    Durmaz, R
    Yang, D
    Yang, ZH
    [J]. MICROBIAL DRUG RESISTANCE, 2005, 11 (02) : 94 - 99
12345